ProShare Advisors’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.82M Sell
18,010
-1,259
-7% -$247K 0.01% 599
2026
Q1
$3.78M Sell
19,269
-9,161
-32% -$1.78M 0.01% 596
2025
Q4
$4.93M Buy
28,430
+1,473
+5% +$268K 0.01% 563
2025
Q3
$5.14M Sell
26,957
-359
-1% -$63.7K 0.01% 545
2025
Q2
$4.91M Buy
27,316
+9,461
+53% +$1.64M 0.01% 550
2025
Q1
$3.02M Buy
17,855
+697
+4% +$115K 0.01% 608
2024
Q4
$2.59M Buy
17,158
+1,970
+13% +$306K 0.01% 647
2024
Q3
$2.36M Sell
15,188
-17,486
-54% -$2.61M 0.01% 654
2024
Q2
$4.47M Buy
32,674
+17,541
+116% +$2.4M 0.01% 524
2024
Q1
$2.01M Sell
15,133
-595
-4% -$77.2K 0.01% 667
2023
Q4
$2.17M Sell
15,728
-1,509
-9% -$198K 0.01% 646
2023
Q3
$2.1M Sell
17,237
-705
-4% -$93.9K 0.01% 639
2023
Q2
$2.52M Buy
17,942
+560
+3% +$77.2K 0.01% 627
2023
Q1
$2.46M Buy
17,382
+1,959
+13% +$280K 0.01% 631
2022
Q4
$2.41M Sell
15,423
-470
-3% -$67.5K 0.01% 594
2022
Q3
$1.95M Sell
15,893
-1,923
-11% -$253K 0.01% 622
2022
Q2
$2.37M Sell
17,816
-7,331
-29% -$999K 0.01% 628
2022
Q1
$3.44M Sell
25,147
-1,536
-6% -$214K 0.01% 623
2021
Q4
$4.62M Buy
26,683
+4,776
+22% +$727K 0.01% 585
2021
Q3
$3.18M Sell
21,907
-1,987
-8% -$291K 0.01% 607
2021
Q2
$3.15M Buy
23,894
+4,618
+24% +$605K 0.01% 612
2021
Q1
$2.47M Buy
19,276
+760
+4% +$93.7K 0.01% 631
2020
Q4
$2.21M Buy
18,516
+1,902
+11% +$232K 0.01% 616
2020
Q3
$1.9M Buy
16,614
+567
+4% +$67K 0.01% 584
2020
Q2
$1.83M Buy
16,047
+2,036
+15% +$216K 0.01% 575
2020
Q1
$1.13M Sell
14,011
-9,672
-41% -$1M 0.01% 579
2019
Q4
$2.53M Buy
23,683
+4,851
+26% +$506K 0.01% 571
2019
Q3
$2.02M Buy
18,832
+1,190
+7% +$122K 0.01% 588
2019
Q2
$1.8M Sell
17,642
-21,054
-54% -$2.02M 0.01% 618
2019
Q1
$3.48M Buy
38,696
+901
+2% +$78.1K 0.02% 483
2018
Q4
$3.15M Sell
37,795
-213
-0.6% -$20K 0.02% 484
2018
Q3
$4.1M Sell
38,008
-1,117
-3% -$123K 0.03% 464
2018
Q2
$4.3M Sell
39,125
-973
-2% -$101K 0.03% 471
2018
Q1
$4.02M Buy
40,098
+1,713
+4% +$175K 0.03% 482
2017
Q4
$3.78M Buy
38,385
+18,265
+91% +$1.73M 0.03% 488
2017
Q3
$1.88M Buy
20,120
+2,042
+11% +$217K 0.02% 575
2017
Q2
$2.01M Sell
18,078
-322
-2% -$34K 0.02% 554
2017
Q1
$1.81M Buy
18,400
+220
+1% +$21K 0.02% 585
2016
Q4
$1.67M Buy
18,180
+3,668
+25% +$316K 0.02% 601
2016
Q3
$1.23M Sell
14,512
-5,916
-29% -$497K 0.02% 628
2016
Q2
$1.66M Buy
20,428
+25
+0.1% +$1.9K 0.02% 579
2016
Q1
$1.46M Sell
20,403
-9,925
-33% -$666K 0.02% 556
2015
Q4
$2.16M Buy
30,328
+1,334
+5% +$89.7K 0.03% 482
2015
Q3
$1.78M Buy
28,994
+453
+2% +$31.7K 0.03% 506
2015
Q2
$2.07M Sell
28,541
-4,561
-14% -$337K 0.03% 499
2015
Q1
$2.54M Sell
33,102
-4,074
-11% -$292K 0.03% 491
2014
Q4
$2.49M Buy
37,176
+9,659
+35% +$610K 0.03% 508
2014
Q3
$1.67M Sell
27,517
-2,588
-9% -$159K 0.02% 823
2014
Q2
$1.77M Sell
30,105
-1,862
-6% -$109K 0.02% 837
2014
Q1
$1.85M Buy
31,967
+4,367
+16% +$234K 0.02% 800
2013
Q4
$1.48M Buy
27,600
+12,872
+87% +$763K 0.02% 865
2013
Q3
$910K Sell
14,728
-11,182
-43% -$669K 0.02% 942
2013
Q2
$1.57M Buy
+25,910
New +$1.54M 0.03% 580

Other funds holding DGX

ProShare Advisors's DGX Position: Q2 2026 in Review

ProShare Advisors reduced its Quest Diagnostics (DGX) stake by 6.5% in Q2 2026, selling an estimated $247K and leaving 18,010 shares worth $3.82M. The position accounts for 0.01% of the portfolio, ranked #599.

ProShare Advisors first reported a position in DGX in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.14M in Q3 2025. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • ProShare Advisors held 18,010 shares of Quest Diagnostics worth $3.82M as of Q2 2026.
  • ProShare Advisors sold 1,259 Quest Diagnostics shares in Q2 2026, an estimated $247K.
  • Quest Diagnostics made up 0.01% of ProShare Advisors's portfolio in Q2 2026, its #599 holding.
  • ProShare Advisors first reported a position in Quest Diagnostics in Q2 2013 and has held it in 53 quarters since.
  • ProShare Advisors's Quest Diagnostics position peaked at $5.14M in Q3 2025.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.